Clinical trial
Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome
NCT00452192 · University of Erlangen-Nürnberg Medical School, Other · Completed
Key facts
| NCT number | NCT00452192 |
|---|---|
| Title | Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome |
| Official title | Detailed Analysis of the Effects of Telmisartan on Renal Perfusion in Patients With Metabolic Syndrome |
| Lead sponsor | University of Erlangen-Nürnberg Medical School, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome |
| Intervention type | Drug |
| Interventions | Telmisartan |
| Enrollment | 30 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Mar 27, 2007 |
| Last update posted | Jul 10, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: